Cargando…

Prediction of individual combined benefit and harm for patients with atrial fibrillation considering warfarin therapy: a study protocol

INTRODUCTION: Clinical prediction rules have been validated and widely used in patients with atrial fibrillation (AF) to predict stroke and major bleeding. However, these prediction rules were not developed in the same population, and do not provide the key information that patients and prescribers...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Guowei, Holbrook, Anne, Delate, Thomas, Witt, Daniel M, Levine, Mitchell AH, Thabane, Lehana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2015
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4636617/ https://www.ncbi.nlm.nih.gov/pubmed/26546146 http://dx.doi.org/10.1136/bmjopen-2015-009518

Ejemplares similares

Can We Predict Individual Combined Benefit and Harm of Therapy? Warfarin Therapy for Atrial Fibrillation as a Test Case
por: Li, Guowei, et al.
Publicado: (2016)

Does Warfarin or Rivaroxaban at Low Anticoagulation Intensity Provide a Survival Benefit to Asian Patients With Atrial Fibrillation?
por: Lin, Dong, et al.
Publicado: (2021)

A Comparative Study of the Clinical Benefits of Rivaroxaban and Warfarin in Patients With Non-valvular Atrial Fibrillation With High Bleeding Risk
por: Liu, Peng-Hui, et al.
Publicado: (2022)

Comparison of Inflammatory Mediators in Patients With Atrial Fibrillation Using Warfarin or Rivaroxaban
por: Martins, Gabriela Lopes, et al.
Publicado: (2020)

Apixaban vs. Warfarin in Atrial Fibrillation Patients With Chronic Kidney Disease
por: Fu, Chung-Ming, et al.
Publicado: (2021)

Is the Risk of Diabetes Lower in Patients With Atrial Fibrillation Treated With Direct Oral Anticoagulant Compared to Warfarin?
por: Liu, Xuyang, et al.
Publicado: (2022)

Population-based cohort study of warfarin-treated patients with atrial fibrillation: incidence of cardiovascular and bleeding outcomes
por: Gallagher, Arlene M, et al.
Publicado: (2014)

Editorial: Antithrombotic Prophylaxis in Patients With Atrial Fibrillation for Stroke Prevention: Evidence From Randomized Clinical Trials, Observational Studies, Methodological Modeling, and More
por: Zhang, Junguo, et al.
Publicado: (2021)

Editorial: Mechanism and prevention of atrial fibrillation
por: Li, Guowei, et al.
Publicado: (2022)

Cost-effectiveness of Direct Oral Anticoagulant vs. Warfarin Among Atrial Fibrillation Patients With Intermediate Stroke Risk
por: Choi, Ju Hee, et al.
Publicado: (2022)

Safety and Effectiveness of Direct Oral Anticoagulants vs. Warfarin in Patients With Atrial Fibrillation and Endoscopy-Diagnosed Peptic Ulcer
por: Wang, Chun-Li, et al.
Publicado: (2021)

Intraocular Bleeding in Patients With Atrial Fibrillation Treated With NOACs VS. Warfarin: A Systematic Review and Meta-Analysis
por: Liu, Fuwei, et al.
Publicado: (2022)

Direct Oral Anticoagulants vs. Warfarin in Hemodialysis Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis
por: Elfar, Sohil, et al.
Publicado: (2022)

Effectiveness and Safety of DOACs vs. Warfarin in Patients With Atrial Fibrillation and Frailty: A Systematic Review and Meta-Analysis
por: Zeng, Shan, et al.
Publicado: (2022)

Risk of Ischemic Bowel Disease in Patients With Atrial Fibrillation Receiving Warfarin or Non-vitamin K Antagonist Oral Anticoagulants
por: Liao, Jo-Nan, et al.
Publicado: (2022)

Efficacy and safety evaluation of rivaroxaban vs. warfarin among non-valvular atrial fibrillation patients undergoing lower extremity revascularization
por: Yu, Qingyuan, et al.
Publicado: (2022)

Renal outcomes of rivaroxaban compared with warfarin in Asian patients with nonvalvular atrial fibrillation: A nationwide population-based cohort study
por: Lee, So-Ryoung, et al.
Publicado: (2023)

Associations of anaemia with bleeding and thrombotic complications in patients with atrial fibrillation treated with warfarin: a registry-based nested case–control study
por: Helin, Tuukka Antero, et al.
Publicado: (2023)

Direct Oral Anticoagulants vs. Vitamin-K Antagonists in the Elderly With Atrial Fibrillation: A Systematic Review Comparing Benefits and Harms Between Observational Studies and Randomized Controlled Trials
por: Shen, Nan-Nan, et al.
Publicado: (2020)

Association of direct oral anticoagulant-proton pump inhibitor cotherapy with adverse outcomes: protocol for a population-based cohort study
por: Wang, Mei, et al.
Publicado: (2022)

Comparison of the Direct Oral Anticoagulants and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Bitar, Yasmin de Souza Lima, et al.
Publicado: (2021)

Direct Oral Anticoagulants vs. Warfarin in Latin American Patients With Atrial Fibrillation: Evidence From Four post-hoc Analyses of Randomized Clinical Trials
por: Liu, Fuwei, et al.
Publicado: (2022)

Balance of benefits and harms of different blood pressure targets in people with multiple chronic conditions: a quantitative benefit-harm assessment
por: Aschmann, Hélène E, et al.
Publicado: (2019)

Net clinical benefit of antithrombotic therapy for atrial fibrillation patients with stable coronary artery disease
por: Lee, So-Ryoung, et al.
Publicado: (2022)

Modified Taiwan Atrial Fibrillation Score for the Prediction of Incident Atrial Fibrillation
por: Liao, Jo-Nan, et al.
Publicado: (2022)

Direct Acting Oral Anticoagulant vs. Warfarin in the Prevention of Thromboembolism in Patients With Non-valvular Atrial Fibrillation With Valvular Heart Disease—A Systematic Review and Meta-Analysis
por: Martha, Januar Wibawa, et al.
Publicado: (2021)

Atrial Fibrillation and Cancer
por: Hajjar, Ludhmila Abrahao, et al.
Publicado: (2021)

Clinical benefits of oral anticoagulants in atrial fibrillation patients with dementia: a systematic review and meta-analysis
por: Wang, Dayang, et al.
Publicado: (2023)

Left atrial appendage exclusion in atrial fibrillation
por: Rozen, Guy, et al.
Publicado: (2022)

Right atrial appendage firing in atrial fibrillation
por: Baptiste, Florian, et al.
Publicado: (2022)

Economic and Clinical Impact of Stroke and Warfarin Use for Patients with Non-valvular Atrial Fibrillation
por: Wang, Li, et al.
Publicado: (2013)

Editorial: Atrial fibrillation in dementia
por: Gotzmann, Michael, et al.
Publicado: (2023)

Safety and effectiveness of appropriately and inappropriately dosed rivaroxaban or apixaban versus warfarin in patients with atrial fibrillation: a cohort study with nested case–control analyses from UK primary care
por: González-Pérez, Antonio, et al.
Publicado: (2022)

Left atrial appendage closure in patients with atrial fibrillation in whom warfarin is contra-indicated: initial South African experience
por: Abelson, Mark
Publicado: (2013)

Non-vitamin K antagonist oral anticoagulants versus warfarin in atrial fibrillation patients with heart failure and preserved, mildly reduced, and reduced ejection fraction: A systemic review and meta-analysis
por: Wulamiding, Kaisaier, et al.
Publicado: (2022)

Preoperative left atrial volume index may be associated with postoperative atrial fibrillation in non-cardiac surgery
por: Oh, Ah Ran, et al.
Publicado: (2022)

Construction and Analysis of the lncRNA-miRNA-mRNA Network Based on Competing Endogenous RNA in Atrial Fibrillation
por: Ke, Xiangyu, et al.
Publicado: (2022)

Murcia atrial fibrillation project II: protocol for a prospective observational study in patients with atrial fibrillation
por: Rivera-Caravaca, José Miguel, et al.
Publicado: (2019)

Association Between GJA1 rs13216675 T>C Polymorphism and Risk of Atrial Fibrillation: A Systematic Review and Meta-Analysis
por: Chen, Xuejiao, et al.
Publicado: (2020)

Integrated Care of Atrial Fibrillation Using the ABC (Atrial fibrillation Better Care) Pathway Improves Clinical Outcomes in Chinese Population: An Analysis From the Chinese Atrial Fibrillation Registry
por: Wang, Yu-Feng, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_emr8v4pn26b7lr5htunf87249r